Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    29
    ...
ATC Name B/G Ingredients Dosage Form Price
A11CC05 D-ESTER G Vitamin D3 - 50000IU 50000IU Capsule 1,187,701 L.L
B03AC FERAPPLIC G Iron trivalent (ferric carboxymaltose) - 500mg/10ml 500mg/10ml Injectable dispersion 34,231,559 L.L
B05XA03 0.9% SODIUM CHLORIDE INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 164,333 L.L
C09DA03 VALUSTAR PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 592,635 L.L
C10AX09 EZETIMIBE BIOGARAN G Ezetimibe - 10mg 10mg Tablet 1,894,818 L.L
G01AA10 CLINDAMYCIN G Clindamycin - 100mg 100mg Ovule 712,876 L.L
J02AC01 CANDIZOL G Fluconazole - 150mg 150mg Capsule 385,235 L.L
L01BC06 CAPECITABINE SPC G Capecitabine - 500mg 500mg Tablet, film coated 12,665,771 L.L
L04AX03 METOJECT G Methotrexate disodium - 15mg/0.3ml 15mg/0.3ml Injectable solution 1,968,729 L.L
N05AX08 DEPIA G Risperidone - 2mg 2mg Tablet, scored 307,164 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 8mg 8mg Tablet 1,671,740 L.L
A02BC02 LUGANOR G Pantoprazole - 40mg 40mg Injectable lyophilised powder for solution 463,050 L.L
A11CC05 D-VITAL G Vitamin D3 - 50,000IU 50,000IU Capsule, hard 712,620 L.L
B05XA03 0.9% SODIUM CHLORIDE INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 688,359 L.L
C07AB03 ATONIUM G Atenolol - 100mg 100mg Tablet 461,207 L.L
C09DA03 VIOSTAN PLUS 160/12.5 G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 668,082 L.L
C10AX09 EZETRALEX G Ezetimibe - 10mg 10mg Tablet 972,686 L.L
J01DD08 BETIXIM 100 G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 348,055 L.L
J02AC01 FLOCAZOLE G Fluconazole - 150mg 150mg Capsule 172,012 L.L
L01BC06 CAPEDA G Capecitabine - 500mg 500mg Tablet, film coated 4,927,423 L.L
L04AX03 METOJECT G Methotrexate disodium - 20mg/0.4ml 20mg/0.4ml Injectable solution 2,134,022 L.L
M04AA01 ALLOPURINOL BIOGARAN G Allopurinol - 300mg 300mg Tablet 212,327 L.L
N02CX01 APIZINE G Pizotifen - 0.25mg/5ml 0.25mg/5ml Syrup 505,541 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 2mg 2mg Tablet 931,283 L.L
N07BC01 BUPRENORPHINE ARROW G Buprenorphine - 2mg 2mg Tablet 563,070 L.L
R05CA12 IVY-CALM G Dried Ivy leaf extract - 35mg/5ml 35mg/5ml Syrup 251,299 L.L
S01XA18 ESTAPORIN G Ciclosporin - 0.05% 0.05% Emulsion 2,815,798 L.L
A02BC02 LUGANOR G Pantoprazole - 40mg 40mg Injectable lyophilised powder for solution 4,146,714 L.L
A11CC05 EURO D HP 50.000 IU G Vitamin D3 - 50,000IU 50,000IU Capsule 1,261,868 L.L
B03AD EURO-FER CF G Folic acid - 0.5mg, Vitamin C - 200mg, Ferrous fumarate - 300mg Capsule 611,448 L.L
    ...
    29
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025